⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31728193 | 1.00 | — | — | |
| SCHEMBL1874677 | 0.82 | SMN1; SMN2 (0.46) | — | |
| SCHEMBL1873497 | 0.79 | RAB9A (0.60) | — | |
| SCHEMBL485115 | 0.78 | — | — | |
| SCHEMBL29725206 | 0.78 | — | — | |
| SCHEMBL10245415 | 0.77 | ESR1 (0.45) | — | |
| SCHEMBL7499051 | 0.77 | HRH3 (0.50) | — | |
| SCHEMBL26394418 | 0.77 | RAB9A (0.54) | — | |
| SCHEMBL7662002 | 0.77 | CYP11B1 (0.40) | — | |
| SCHEMBL1193384 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-12022832-B2 | Compounds and methods for treating nematode infections | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2024-07-02 | — | — | US | disclosed |
| US-11999730-B1 | AKT1 modulators | ALTEROME THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240174667-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024084390-A1 | COMPOUNDS FOR THE ACTIVATION OF AMPK | PFIZER INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| EP-3340983-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| WO-2007056220-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056228-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (GB) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| EP-0813608-B1 | OSMIUM-CONTAINING REDOX MEDIATOR | ROCHE DIAGNOSTICS CORP (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-0813608-A4 | OSMIUM-CONTAINING REDOX MEDIATOR | ROCHE DIAGNOSTICS CORP (US) | 2000-02-09 | — | — | EP | disclosed |
| US-5846702-A | Reagent including an osmium-containing redox mediator | BOEHRINGER MANNHEIM CORPORATION (US) | 1998-12-08 | — | — | US | disclosed |
| EP-0813608-A1 | OSMIUM-CONTAINING REDOX MEDIATOR | BOEHRINGER MANNHEIM CORPORATION (US) | 1997-12-29 | — | — | EP | disclosed |
| US-5589326-A | FOR ELECTROCHEMICAL BIOSENSORS | BOEHRINGER MANNHEIM CORPORATION (US) | 1996-12-31 | — | — | US | disclosed |
| WO-1996025514-A1 | OSMIUM-CONTAINING REDOX MEDIATOR | BOEHRINGER MANNHEIM CORPORATION (US) | 1996-08-22 | — | — | WO | disclosed |